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Accelerated vascular calcification is a severe complication of
chronic kidney disease contributing to high morbidity and
mortality in patients undergoing renal replacement therapy.
Sodium thiosulfate is increasingly used for the treatment of
soft tissue calcifications in calciphylaxis. Therefore, we
determined whether it also prevents development of
vascular calcifications in chronic kidney disease. We found
that uremic rats treated by thiosulfate had no histological
evidence of calcification in the aortic wall whereas almost
three-fourths of untreated uremic rats showed aortic
calcification. Urinary calcium excretion was elevated and the
calcium content of aortic, heart, and renal tissue was
significantly reduced in the thiosulfate-treated compared to
non-treated animals. Sodium thiosulfate treatment
transiently lowered plasma ionized calcium and induced
metabolic acidosis. It also lowered bone strength in the
treated animals compared to their normal controls. Hence,
sodium thiosulfate prevented vascular calcifications in uremic
rats, likely by enhancing acid- and/or chelation-induced
urinary calcium loss. The negative impact on rat bone
integrity necessitates a careful risk–benefit analysis before
sodium thiosulfate can be used in individual human patients.
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Cardiovascular diseases account for at least 50% of
deaths in patients with chronic kidney disease (CKD).1
Although a single cause of this excessive cardiovascular
mortality has not been identified, one contributing factor is
vascular calcification that has been shown to negatively
influence a number of surrogate markers for cardiovascular
mortality, including arterial stiffness and left ventricular
hypertrophy.2,3
Sodium thiosulfate (STS, Na2S2O3) is an agent with strong
antioxidant properties4,5 and also probably chelates calcium
to form soluble calcium thiosulfate complexes.6–8 STS has
been used for the treatment of cyanide toxicity in humans for
more than a century.9 Furthermore, it has been prescribed for
the topical treatment of skin diseases like acne and pityriasis
versicolor,9and in recent years for the prevention of
carboplatin and cisplatin-induced oto- and nephrotoxici-
ty5,9,10and for the treatment of nephrogenic systemic fibrosis
in dialysis patients.11,12 STS has been reported to prevent
calcium nephrolithiasis in humans6–8,13 and genetically
hypercalciuric rats.14 Moreover, accumulating evidence
indicates that STS is a successful treatment for calciphylaxis,
a disease characterized by abnormal calcium deposits in soft
tissues.15–18 On the basis of these reports and in view of the
favorable short-term safety profile reported for STS, we
hypothesized that STS might be a promising agent for the
prevention of vascular calcifications in CKD.
RESULTS
Adenine-induced nephropathy
The experimental protocol is illustrated in Figure 1. Male
Wistar rats (6-week old) were fed an adenine containing diet
(0.75%) for 4 weeks to induce CKD. Induction of CKD
was evidenced by rising serum creatinine concentrations
(Figure 2a). Furthermore, uremic animals exhibited a
reduced weight gain (Figure 2b), were polyuric (Figure 2c),
anemic (Table 1), and exhibited high serum phosphate and
parathyroid hormone (PTH) concentrations (Table 1). Inter-
estingly, in rats concomitantly given adenine and STS (early
treatment, ET rats at 4 weeks), serum creatinine was
significantly higher than in rats given adenine only (uremic
control, UC and late treatment, LT rats, Po0.001). At week
10, this effect was no longer observed. No difference in total
serum calcium concentrations was detected among groups at
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the end of the experiment (Table 1). Serum bone turnover
markers osteocalcin and deoxypyridinoline crosslinks were
strongly increased in the uremic animals (Table 1). No
differences between uremic STS-treated and untreated rats
were found for all variables mentioned. All adenine-treated
uremic rats survived the complete course of STS treatment
and no clinically detectable adverse events were noted before
the animals were killed.
Vascular calcifications and calcium content of organs
STS prevented vascular calcifications as shown by histologic
sections through the aorta and the coronary vessels of a
representative STS-treated rat (Figure 3). Although 8 of 11
(73%) untreated uremic animals showed major vascular
calcifications, 0 of 18 (0%) of the STS-treated uremic animals
had aortic calcifications (Po0.001; Table 2). In accordance with
this result, the calcium and phosphorus content of aortic tissue
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Figure 1 | Experimental protocol for the adenine treatment of rats. Uremia was induced in 6-week-old male Wistar rats by a 4-week
diet containing 0.75% adenine. STS was given intraperitoneally three times a week, as indicated. NUC, nonuremic control animals; UC,
uremic control animals; ET, early treatment with STS; LT, late treatment with STS.
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Figure 2 | Characteristics of the adenine-induced renal failure model. (a) Serum creatinine was higher in all uremic groups at weeks 4
and 10 (***Po0.001) when compared to NUC. At week 4, but not at week 10, ET animals were more uremic than LT and UC animals
($$$Po0.001). (b) Body weight was lower in all uremic groups at weeks 4 and 10 when compared to NUC (***Po0.001). At week 4, but not
at week 10, ET and LT animals were lighter than UC animals ($$Po0.01). (c) Progressive polyuria was observed in all uremic groups when
compared to NUC animals (***Po0.001). NUC, nonuremic control animals; UC, uremic control animals; ET, early treatment with STS; LT, late
treatment with STS.
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of STS-treated animals was significantly reduced (Po0.01;
Figure 4). No difference in the mineral content of the vessel walls
of ET and LT animals was found (Figure 4).
As for the aortic tissue, the calcium content of heart and
kidney tissue was significantly lower in the STS-treated when
compared to untreated uremic rats (Po0.05; Figure 5a
Table 1 | Blood values at the end of the experiment (blood was taken 24 h after the last STS application)
Nonuremic controls
(n=12)
Uremic controls
(n=11)
Early treatment
(n=10)
Late treatment
(n=8)
Uremia  + + +
STS treatment +  + +
Blood chemistry
Serum creatinine (mmol/l) 24±2 148±38*** 179±73*** 155±34***
Correcteda Ca++ (mmol/l) 3.24±0.14 3.39±0.14* 3.35±0.08 3.23±0.16
Phosphate (mmol/l) 2.42±0.43 3.23±0.31** 3.56±0.67** 2.91±0.79**
PTH (pg/ml) 45±17 563±108*** 403±82*** 534±189***
Osteocalcin (ng/ml) 225±71 1284±489*** 1458±423*** 1302±431***
Serum DPD (nmol/l) 33±6 99±24*** 109±24*** 113±24***
Matrix Gla protein (nmol/l) 11.5±2.36 7.0±1.6** 10.2±1.43$ 9.9±2.0$
Hemoglobin (g/l) 149±11 111±15*** 105±15*** 107±15***
STS, sodium thiosulfate; PTH, parathyroid hormone; DPD, deoxypyridinoline.
Comparison with nonuremic controls: *Po0.05, **Po0.01, ***Po0.001.
Comparison with uremic controls: $Po0.05.
a Total calcium corrected for albumin.
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Figure 3 | Representative vascular histology of STS-treated and untreated animals. Micrographs show aortic and coronary media
calcifications as assessed by Alizarin red and von Kossa stains. Calcifications are present in uremic animals without treatment, whereas no
calcifications are visible in STS-treated uremic animals; *magnification  4, **magnification  10.
Table 2 | Prevalence of aortic calcifications in STS-treated and untreated animals
Nonuremic
controls (n=12)
Uremic controls***
(n=11)
Early treatment***
(n=10)
Late treatment***
(n=8)
Uremia  + + +
STS treatment +  + +
Aortic wall
Presence of histologic calcifications (n) 2 8 0 0
Severity of calcification ++ (n=1) +++ (n=8)
+++ (n=1)
STS, sodium thiosulfate.
Number of animals (n) with aortic calcifications assessed by histology in each treatment group and severity of calcifications (none, +, ++, +++).
***Fisher’s exact test Po0.001 for the comparison of STS-treated versus untreated uremic animals (0 of 18 versus 8 of 11).
1446 Kidney International (2008) 74, 1444–1453
o r i g i n a l a r t i c l e A Pasch et al.: Thiosulfate prevents vascular calcifications
and b). Conversely, urinary calcium excretion was several
fold higher in STS-treated than in untreated uremic animals
(24 h urinary calcium excretion of UC versus ET and LT:
11±7 mmol/24 h versus 57±21 mmol/24 h and 59±18 mmol/
24 h, respectively, Po0.001; Figure 6). Despite this marked
hypercalciuria in STS-treated rats, neither nephrocalcinosis
nor kidney stones were encountered in any animal (data not
shown).
Mechanisms of action of STS
To investigate the mechanism of action of STS, male Wistar
rats were 5/6 nephrectomized at age of 7 weeks. The
experiment was carried out at age 10 weeks, when the mean
serum creatinine was 188±32 mmol/l. A single dose of STS
was given i.p. (0.4 g/kg) and blood and urine samples were
taken at 0, 15, 30, 45, 60, 90, 120, and 180 min. Blood was
drawn under isoflurane anesthesia, where hyperventilation
was consistently observed. Ionized calcium dropped signifi-
cantly (Po0.05) and transiently at 15 min, but normalized at
30 min (Figure 7a) when in turn PTH levels had risen
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Figure 4 | Calcium and phosphorus content per gram of aortic tissue. Significantly lower amounts of (a) calcium and (b) phosphorus are
found in nonuremic controls (NUC) and STS-treated uremic animals (ET, LT) when compared to uremic, untreated controls (UCs). Calcium
and phosphorus contents were not different between NUC, ET, and LT rats. **Po0.01 and ***Po0.001 when compared to UC.
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Figure 5 | Calcium content per gram of (a) heart and (b) kidney tissue. Heart calcium content was reduced in all STS-treated groups
when compared to untreated uremic animals. Also, kidney calcium content was higher in untreated uremic controls when compared to
uremic STS-treated rats. Calcium content in heart and kidney tissues was not different in NUC, ET, and LT rats. *Po0.05, **Po0.01,
***Po0.001 when compared to UC.
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Figure 6 | Calciuria in STS-treated and untreated rats. Urine
was collected in metabolic cages at the end of the experiment.
STS-treated rats excreted more calcium than untreated uremic
rats (**P¼ 0.01 and ***Po0.001 for NUC, ET, and LT when
compared to UC). NUC, STS-treated nonuremic control animals;
UC, uremic control animals; ET, early treatment with STS; LT, late
treatment with STS.
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significantly after 15 and 120 min (Figure 7c; Po0.01). The
concentrations of total calcium started rising over the
baseline concentration at 45 min after STS application
(Figure 7b; Po0.001). The resulting difference between
ionized and total calcium concentration is best interpreted by
the presence of a calcium-binding agent, a notion also
supported by the induction of a sustained high anion gap
(Figure 7d). The anion gap increase was followed by a decline
in the serum bicarbonate und urinary pH (Figures 7e, f and
8b). After STS application, urinary total calcium excretion
increased (Figure 8a; Po0.05 at 60 min and Po0.01 at 120
and 180 min). The patterns of changes described here were
also observed in an experiment performed in healthy rats
(data not shown).
To confirm the suspected calcium-chelating properties of
STS, human blood samples were incubated with rising
concentrations of STS in vitro. This resulted in a progressive
decline of ionized calcium levels, in the presence of stable
bicarbonate, pCO2 and pH values (Figure 9). An STS
concentration of 7–10 mmol/l was detected in vivo in rats
15 min post STS application, and caused a decline of ionized
calcium of about 0.05 mmol/l. This value was comparable to
the decline detected at 5–10 mmol/l STS in the in vitro
experiment (Figure 9).
To further investigate the mechanism of action of STS, the
calcification inhibitor plasma matrix g-carboxyglutamate
(Gla) protein (MGP) was measured from plasma taken at
the end of the experiment with the adenine CKD rat model
(Table 1). These measurements revealed the highest MGP
levels in non-UCs (11.5±2.36 nmol/l), and the lowest levels
in untreated uremic animals (7.0±1.6 nmol/l). STS-treated
uremic animals exhibited significantly higher MGP levels
than untreated uremic animals (ETþ LT animals: 10.2±1.43
and 9.9±2.0 nmol/l, Po0.05 when compared to untreated
uremic UC controls).
STS and bone
As the hypercalciuria induced by STS can potentially
jeopardize bone integrity, we morphologically and function-
ally analyzed femoral bones of STS-treated (STS 0.4 g/kg i.p.
five times per week) and untreated animals. Microcomputed
tomograms (CTs) of rat femurs revealed clear morphological
differences between bones from uremic and nonuremic
animals, with bones from uremic animals exhibiting reduced
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Figure 7 | Responses to STS application in rats. Blood was taken from anesthetized uremic 5/6 nephrectomized rats before and after STS
application at the time points indicated. At 15 min after STS dosing, the ionized calcium concentration was diminished (*Po0.05) when
compared to baseline and rose again after 30 min when compared to the lowest concentration at 15 min (yPo0.05 and yyPo0.01), but not
when compared with baseline values. The other significance values in Figures 7 a–f are given in comparison to baseline (0-value)
concentrations: *Po0.05, **Po0.01, ***Po0.001.
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mineralization and multiple cysts (Figure 10). Functional
studies on bone stability revealed that the stiffness (measured
in Newton per mm, N/mm) of femurs was significantly lower
in uremic than nonuremic rats (Po0.001; Figure 11a), and
that bone stiffness was not affected by STS treatment. The
load needed to fracture the femurs, however, was significantly
lower in nonuremic STS-treated when compared to non-
uremic untreated animals (Po0.01; Figure 11b). This trend
was also present in the uremic animals, although significance
was not reached (P¼ 0.06).
Discussion
The present investigation demonstrates for the first time that
the prophylactic application of STS prevents vascular
calcifications in uremic rats. In line with the absence of
vascular calcifications, the calcium and phosphate contents of
the aorta, heart, and kidney was markedly lower in STS-
treated than in untreated uremic rats (Figures 4 and 5).
Calcium concentrations found in our tissue specimens were
comparable to previous investigations using the adenine
CKD rat model.19 Interestingly, uremic animals also showed
calcifications of the coronary arteries, which were not found
in the STS-treated animals (Figure 3).
The mechanisms responsible for the prevention of
calcifications deserve consideration. STS treatment enhanced
urinary calcium excretion (Figures 6 and 8) in all animals.
Hypercalciuria presumably induced a negative net calcium
balance as evidenced by the low calcium contents in various
tissues of these animals (Figures 4 and 5), an effect also
previously observed by 99Tc-MDP scans in humans treated
with STS for calciphylaxis.15,18 One possible mechanism to
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Figure 10 | Bone morphology of STS-treated and untreated
uremic and nonuremic animals. Microcomputed tomography
slices of rat femurs (a, c) with and (b, d) without STS treatment.
Nonuremic rats had normal bone architecture, whereas a reduced
mineralization and cystic transformations were present in the
uremic animals. These findings were independent of STS
treatment.
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induce hypercalciuria is the direct chelation and ensuing
urinary excretion of calcium, which has also been shown for
the chelator ethylenediaminetetraacetic acid.20 The conten-
tion of a direct calcium chelation by STS is supported by a
decline of serum ionized calcium concentrations when
exposed to STS in vivo and in vitro (Figures 7a and 9a) and
a rise in total calcium concentrations in the presence of an
elevated anion gap attributable to STS (Figure 7b and d).
Measurements of thiosulfate after STS application in rats
revealed concentrations which decreased ionized calcium
significantly in vivo and in vitro. Thus, it is likely, that STS
contributes, at least in part, to the prevention of calcifications
by its chelation properties.
A second mechanism for the prevention of vascular
calcifications by STS in rats might be the induction of
acidosis. Such an effect of acidosis was shown by Mendoza
et al.21 However, in their report acidosis was induced by the
continuous application of ammonium chloride with the
drinking water, whereas in our model elevated anion gap was
present only for 6–8 h every 2 days, directly after STS
application. Acidosis has long been known to induce
hypercalciuria and negative calcium balance.22 Pathophysio-
logically, hypercalciuria is acutely induced by the physico-
chemical dissolution of calcium carbonate from bone,
whereas chronically, complex cellular mechanisms inhibiting
bone formation and stimulating bone resorption predomi-
nate.23–25 STS increased the acid load in our rats, thus it is
reasonable to conclude that both mechanisms discussed so
far—calcium chelation and induction of acidosis—possibly
contribute to the vascular calcifications-inhibiting effects
of STS.
As a third mechanism, STS might change the availability
or function of factors affecting the extracellular matrix,
thereby modulating the calcifying propensity of the vessel
walls in uremia. Often considered candidates are fetuin-A,
MGP, carbonic anhydrase, and osteoprotegerin.26,27 Here,
plasma MGP concentrations were measured and revealed
higher MGP levels in uremic STS-treated versus untreated
rats (Table 1), suggesting the possibility of additional
therapeutic effects of STS by modulating the availability of
locally acting calcification inhibitors.
Microinflammation and oxidative stress are involved in
the development of vascular calcifications.28 STS has been
reported to exhibit antioxidant properties.4,9 Therefore, the
protective effect of STS on the vasculature in our rats might,
as a fourth potential mechanism, have been due to its free
oxygen radical scavenger properties.29 This hypothesis was
not addressed by our work and clearly deserves a special focus
in the future.
Hypercalciuria is associated with nephrocalcinosis and
nephrolithiasis.30 Despite induction of pronounced hyper-
calciuria in our STS-treated rats, no renal calcifications or
kidney stones were observed. One possible explanation for
the absence of kidney stones and nephrocalcinosis might be
the relatively short observation time of 6–8 weeks, probably
too short a period for these abnormalities to develop.
Previously, oral STS has been successfully given as an
inhibitor of renal calcium crystal precipitacion for several
months in humans6–8 and in genetically hypercalciuric stone-
forming rats.14 Thus, STS appears to inhibit rather than to
promote stone formation. In our experiment this ‘stone
inhibitory propensity’ is probably reflected by the low kidney
calcium content of STS-treated rats (Figure 5b).
An important observation concerning hypercalciuria is its
association with reduced bone mineral density,31,32 a causal
relationship supported by the known hypercalciuria-reducing
and thereby bone-protecting properties of thiazide diure-
tics.33 As STS induced not only calciuria but also an elevated
anion gap and elevated PTH concentrations, the effect of STS
on bone was investigated. CT studies of the femoral bones
showed marked differences between uremic and nonuremic
animals, but no morphological differences between STS-
treated and untreated bones (Figure 10). Functional studies
on bone stiffness and fracture load again revealed differences
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between uremic and nonuremic bones (Figure 11a and b).
Furthermore, STS-treated bone from nonuremic animals
fractured at lower applied forces than bone of untreated
nonuremic rats, a pattern that was also observed when
uremic animals with and without STS treatment were
compared. Our fracture studies underline the necessity to
monitor bone mineral density in humans treated with STS
for prolonged time episodes. Furthermore, the effect of STS
on trabecular bone has to be investigated.
Besides the adverse effects on bones, STS was well
tolerated by the animals without side effects, and no rat
died before the end of the experiment. Interestingly, and
contraintuitively, we observed aortic calcifications in two
healthy nonuremic rats treated with STS, but in none of the
uremic rats treated with STS (Table 2). We have no evidence-
based explanation for this finding. However, one might
speculate that the presumably more rapid excretion of STS by
normal than impaired kidneys attenuates the therapeutic
effect of STS. In support of this assumption, a kinetic
study performed in dogs revealed a rapid renal excretion of
STS in healthy dogs and elevated serum STS levels in
anephric dogs.34 This suggests that the effectiveness of STS
treatment and the ‘exposure time’ of tissues with deposited
minerals (as the calcified vasculature) to this agent increases
with the degree of renal function impairment. In anuric
patients, the effectiveness of STS will depend, at least
partially, on the effect of dialysis to remove calcium and
STS. To date, there are no data describing STS pharmaco-
kinetics in uremic humans or animals undergoing renal
replacement therapy.
In summary, we show for the first time that STS treatment
prevents aortic calcifications in uremic rats. This effect is
currently best explained by the combined calcium-chelating
and acidosis-inducing properties of STS, which cause
hypercalciuria and a negative net calcium balance. Further-
more, elevated MGP levels might have a protective effect on
the vasculature. In light of the bone-damaging properties of
STS, further studies focussing on the prevention of this side
effect are needed before long or medium term studies in
humans are be performed with this promising agent.
METHODS
Animals
Adenine rat model. An illustration of the experimental design
is shown in Figure 1. Experiments were performed with all
permissions required by the Swiss authorities. All rats were pair-
housed with a 12/12 h light/dark cycle and had unlimited access to
water and standard rat chow (calcium 1.05%, phosphorus 0.8%,
protein 18.5%). Male Wistar rats (6-week old; Charles River,
Sulzfeld, Germany) were used for this experiment. A total of 12 rats
(nonuremic STS-treated controls, NUC, n¼ 12) were fed standard
rat chow, whereas 44 additional rats received standard rat chow
containing 0.75% adenine (Sigma-Aldrich, Buchs, Switzerland) for 4
weeks to induce renal failure. Adenine-induced nephropathy has
previously been shown to be a useful tool for in vivo studies of
vascular calcifications.19,35 Uremia was randomly defined as a serum
creatinine concentration above 100mmol/l at the end of the
experiment (25 mmol/l is about normal in rats this age). This
definition led to the following drop out rates: UCs (n¼ 3, 11
animals left for analysis), uremic rats to receive ET with STS (ET,
n¼ 4, 10 animals left for analysis), uremic rats to receive LT with
STS (LT, n¼ 8, 8 animals left for analysis).
For the method of blood drawing, please refer to the section ‘5/6
nephrectomy rat model’ (below). All animals were killed by
barbiturate injection after 10 weeks (that is at age 16 weeks).
5/6 nephrectomy rat model
Acid–base studies and calcium chelation experiments were per-
formed in 24 5/6 nephrectomized 12-week-old male Wistar rats
(Charles River). A single dose STS (0.4 g/kg body weight) was given
i.p. Blood (1–1.5 ml) was taken only twice from each rat, and the
experiment was designed to obtain blood values at all of the
following time points: 0 (12 rats), 15 (6 rats), 30 (6 rats), 45 (6 rats),
60 (5 rats), 90 (4 rats), 120 (5 rats), and 180 (4 rats) minutes. Blood
was taken from the sublingual veins while the animals were under
short isoflurane anesthesia. As rats regularly empty their bladder
while under anesthesia, urine samples were also obtained at the
same time points.
Sodium thiosulfate administration
Sodium thiosulfate (Ko¨hler Chemie GmbH, Alsbach, Germany) was
diluted 1:3 with normal (0.9%) saline and given i.p. three times a
week in a dosage derived from STS usage in humans (0.4 g/kg body
weight).15,16 STS treatment was started after 2 weeks of adenine diet
in the ET group and after 4 weeks in the LT group, resulting in a
total treatment duration of 8 and 6 weeks, respectively (Figure 1).
NUC animals were also treated with STS for 6 weeks. Control (UC)
animals received normal saline i.p.
Blood and urine chemistry
In the adenine rat model, blood was drawn from a sublingual vein at
baseline, after 4 weeks and at the end of the experiment. Blood was
allowed to clot and serum was removed and stored at 80 1C until
assayed. Standard laboratory methods were used to determine
serum calcium, phosphate, albumin, creatinine, urea, and hemo-
globin values. Serum calcium levels were corrected for albumin
levels with the following conventional formula: TCa corr¼TCa
(mmol/l)þ 0.02([40 (g/l)albumin (g/l)).36 Serum concentrations
of PTH (Immutopics Inc., San Clemente, CA, USA), osteocalcin
(Rat-MID Osteocalcin; Nordic Bioscience Diagnostics, Herlev,
Denmark), and deoxypyridinoline crosslinks (Quidel Inc., San
Diego, CA, USA) were measured by using rat-specific assays. The
assay used for MGP (Biomedica GmbH, Vienna, Austria) is also rat
specific, but does not discriminate between active (g-carboxylated)
and inactive (uncarboxlated) MGP. It has however been reported to
identify an increased vascular calcification risk.37 STS serum
concentrations were determined using a specific high-performance
liquid chromatography method with conductimetric detection as
described elsewhere.38,39 Urine was collected in metabolic cages after
four weeks and at the end of the experiment, and calcium and
creatinine in the urine were measured by standard laboratory methods.
Assessment of calcifications
Vascular calcifications were assessed by histology and biochemical
methods. Aortas were dissected from the heart to the iliac
bifurcation immediately after killing and fixed in 4% buffered
formalin for a minimum of 48 h.19 Calcium in the aortic walls was
visualized by von Kossa’s (calcium-phosphate) and Alizarin red
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(calcium) stains. Two different observers, blinded for the treatment
groups, graded the vessel walls for the presence (yes/no), and
severity (0, þ , þ þ , þ þ þ ) of calcium deposits.
Calcium and phosphorus was extracted from thoracic aorta
(approximately 2 cm), heart and kidney tissue with 0.5 M HCl for
24 h after homogenization as previously described.19 Concentrations
were determined colorimetrically in the supernatant using specific
colorimetric calcium (total) and phosphorus assays (BioAssays
Systems, Hayward, CA, USA). The amounts of calcium and
phosphorus extracted from tissue were normalized for tissue weight
(mmol/g).
In vitro chelation of calcium by STS
The calcium chelating properties of STS were assessed in vitro by
incubating different amounts of a concentrated STS solution in 1 ml
heparinized human blood drawn from healthy volunteers (n¼ 7) to
obtain final STS concentrations of 0, 5, 10, 15, 20, 40, and 80 mmol/l.
The dilution effect of the added STS solution was negligible as the
maximal volume added was only 25 ml (corresponding to final
concentration of 80 mmol/l). The samples were measured immedi-
ately at 37 1C under anoxic conditions. As calcium chelation at
physiologic pH and temperature is a rapid process, occurring within
seconds (own analyses, data not shown), samples were measured
2 min after incubation with STS with a Radiometer ABL800 Basic
analyzer (Radiometer GmbH, Thalwil, Switzerland). This device
measures pH and pCO2 directly, whereas bicarbonate is derived
from pH, pCO2, oxygen saturation, and hemoglobin concentrations
according to an algorithm described in the user’s manual of the
ABL800 device.
Bone analyses
The bone integrity experiments were performed with femoral bones
from 16-week-old male Wistar rats made uremic according to the
standard adenine protocol (Figure 1). Four groups of animals were
used: rats with normal renal function (n¼ 6), rats with normal renal
function treated with STS (n¼ 10), uremic rats (n¼ 9), and uremic
rats treated with STS (n¼ 15). STS treatment was performed five
times per week (0.4 g/kg i.p.). The quality of femoral bone from
STS-treated and untreated uremic and nonuremic rats was assessed
by micro-CT and by functional stiffness (compliance) and fracture
studies. Both methods have been used and described elsewhere.40,41
Micro-CTs were performed using a SkyScan-Microtomograph
(Microphotonics Inc., Irvine, CA, USA). Formalin-fixed bones were
placed in the scanner, sliced uniformly 10 mm below the trochanter
mayor and analyzed for the presence of demineralization and cysts.
Assessment of functional bone stability was performed in compres-
sion mode (four-point bending) using a uniaxial electromechanical
testing machine (Instron 5866; Instron Inc., Norwood, MA, USA)
equipped with a 1 kN load cell. Rat femurs were placed in the
machine, and in a first step, stiffness (compliance) was tested by
measuring bone distensibility in mm at a given force (in Newton, N).
In a second step, bones were exposed to escalating forces until fracture
occurred and the maximal enduring load (N) was determined. These
analyses were carried out in the laboratory premises of the
Arbeitsgemeinschaft fu¨r Osteosynthese, Davos, Switzerland.
Statistics
All results, including the graphs in the figures, are given as
means±s.d. Statistical analysis and graphs were performed using the
GraphPad software (GraphPad Software Inc., La Jolla, CA, USA).
Methods to compare the four groups included analysis of variance
with Bonferroni correction for parametric variables and the
Kruskal–Wallis test for nonparametric variables. Two group
comparisons were carried out with the two-sided Mann–Whitney
U-tests for unpaired observations. Contingency table analyses were
carried out by two-sided Fisher’s exact test.
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